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Following potentially curative surgery for breast cancer the pres-
ence of histologically evident tumour cells in the axillary lymph
nodes is used to select high-risk patients for adjuvant therapy;
however, 30% of histologically node-negative patients also
develop metastatic disease. More accurate staging, in particular
detection of occult metastatic disease, may enable effective treat-
ment strategies to be extended to more high-risk patients.
Polymerase chain reaction (PCR) is up to 100 times more sensi-
tive than conventional techniques in detecting circulating tumour
cells and submicroscopic metastases (Ghossein and Rosai, 1996).
However, the extreme sensitivity of PCR also confers an inherent
disadvantage to produce false positive results. Furthermore, the
central question of whether PCR-detected metastases reliably
predicts relapse remains unanswered for many tumour types.
Whilst lacking specific markers expressed by breast cancer cells a
number of research groups have used cytokeratins 18 and 19,
epithelial mucin (MUC1), carcinoembryonic antigen (CEA), CD
44 and maspin as transcript markers for the detection of submicro-
scopic metastases in lymph nodes, bone marrow or peripheral
whole blood by reverse transcription PCR (RT-PCR) (Matsumura
and Tarin, 1992; Datta et al, 1994; Gerhard et al, 1994; Noguchi et
al, 1994, 1996a, 1996b; Schoenfeld et al, 1994, 1996, 1997;
Brown et al, 1995; Mori et al, 1995; Gunn et al, 1996; Luppi et al,
1996; Yun et al, 1997; Eltahir et al, 1998; Lockett et al, 1998).
However, there appears to be conflicting data regarding the speci-
ficity of some of these cell type specific markers in particular
MUC-1 (Noguchi et al, 1994; Hoon et al, 1995), CD44
(Matsumura and Tarin, 1992; Eltahir et al, 1998) and K19
(Traweek et al, 1993; Schoenfeld et al, 1994, 1996; Burchill et al,
1995; Krismann et al, 1995; Gunn et al, 1996; Dingemans et al,
1997; Yun et al, 1997; Eltahir et al, 1998). Maspin expression has
been previously reported as being a specific marker for breast
cancer (Luppi et al, 1996); however, there have been no larger
confirmatory studies to assess the accuracy and reproducibility of
these findings. Although discrepancies in specificity may be
attributed to RT-PCR methods employed including primer design,
single-step PCR, two-stage PCR or signal detection by Southern
blotting, clearly there is need to establish which markers may have
potential in the diagnosis of minimal residual disease in breast
cancer.
In an attempt to define a suitable cell type-specific marker for
RT-PCR detection of submicroscopic lymph node metastases in
breast cancer, we have examined a panel of candidate genes, with
particular emphasis on sensitivity and specificity of gene expres-
sion in tissue from patients with and without breast cancer.
MATERIALS AND METHODS
Patients and tissue collection
Ethics committee approval to undertake this study was obtained.
All patients undergoing either mastectomy or wide excision and
axillary dissection were eligible for inclusion into the study. Fully
informed written consent for collection of tissues was obtained.
Mastectomy or wide excision specimens with axillary nodes were
collected fresh from the operating theatre and lymph nodes were
dissected prior to examination of the tumour on a clean UV irradi-
ated chopping board with a sterile surgical blade to prevent epithe-
lial cell contamination. Lymph nodes were bisected, with half
submitted for routine histology and half taken for examination by
RT-PCR. After lymph node dissection specimens of tumour and
normal breast were taken from each specimen. Tumour grade
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carcinoma in situ (DCIS) were recorded. Oestrogen and proges-
terone receptor status was assessed by immunohistochemistry
using the 1D5 monoclonal and polyclonal antibody respectively
(Dako). As a control group, lymph nodes were collected from
patients undergoing surgery for histologically confirmed benign
colorectal disease. Routine steps were taken in control specimens
to avoid any luminal contamination prior to lymph node dissec-
tion.
Markers
In common with other research groups we have developed sensi-
tive assays for cytokeratins (K) 8 and 19 and MUC1 mRNAs using
RT-PCR. In addition we have also investigated expression of
stromelysin 3 (ST3), cytokeratin 16 (K16) and maspin. ST3 is a
matrix metalloproteinase implicated in mammary carcinoma
progression. In node-positive patients with infiltrating ductal
carcinoma, multivariate analysis has revealed that ST3 level is a
strong, independent prognostic parameter for disease-free survival
(Ahmad et al, 1998). K16 has been reported as having expression
limited to skin and breast tissue (Adams et al, 1995), making it a
good potential marker of submicroscopic spread of breast cancer.
To control for the presence of epithelial cell contamination in
the control population we used an assay for cytokeratin 20 (K20)
which is a sensitive and specific gastrointestinal epithelial cell-
specific marker (Gunn et al, 1996; Yun et al, 1997).
Cell lines
Both MCF-7 and T47-D breast cancer cell lines were used to
develop the assays. These cell lines are known to express MUC1
(Abe and Kufe, 1993) and K19 (Moll et al, 1982). Additionally
MCF-7 has been reported to express maspin (Luppi et al, 1996).
Both cell lines were grown and maintained in RPMI-1640 supple-
mented with 10% fetal calf serum at 37°C in 5% carbon dioxide.
RNA extraction
Bisected lymph nodes and tissue samples from the resected spec-
imen were collected into 1.5-ml microcentrifuge tubes containing
500 ml of 4 M guanidinium solution and manually homogenized
using sterile DNA-free techniques. Total RNA from tissue samples
and cell lines was extracted using a modification of the
acid–guanidine isothiocyante–phenol–chloroform method
(Chomczynski and Sacchi, 1987). RNA samples were measured
by spectrophotometry at 260 nm and stored at –80°C until
required. Rigorous steps were taken to avoid epithelial cell conta-
mination, by physical separation of the component stages of spec-
imen dissection, RNA extraction, cDNA synthesis, PCR and PCR
product electrophoresis. All specimens were accompanied by a
reagent only negative control.
Reverse transcription
RNA samples were treated with RNase-free DNase 1 (Gibco
BRL) prior to cDNA synthesis. cDNA was synthesized from a
maximum of 2.5 mg of DNase-treated total RNA, with 200 units
of M-MLuV Reverse Transcriptase (GibcoBRL) primed with
random hexamers (Boehringer Mannheim), using the manufac-
turer’s method in a total volume of 10 ml. Reverse transcriptase
minus controls were prepared for each DNase-treated RNA
sample. One-twentieth of synthesized cDNA was used for PCR.
Oligonucleotide primers
Custom PCR primers (GibcoBRL) were designed as follows:
K8 F GCG GCA GCT GCG TGA GTA
K8 R GCT GAG GCC GGG GCT TGT GAG
K16 outer F TCA ATG ACC GCC TGG CCT CTT A
K16 outer R CAG GGC CAG TTC GTG CTC ATA
K16 inner F CAA CGC CGA CCT GGA AGT G
K16 inner R CAA TGG TGG CCG CAA TGA T
K19 F CCA AGA TCC TGA GTG ACA TGC GAA G
K19 R TGC AGC TCA ATC TCA AGA CCC TGA A
Maspin F CAA GTG GGT GCT AAA GGT GAC
Maspin R CAA AGT GGC CAT CTG TGA G
MUC1 F CGT CGT GGA CAT TGA TCC TAC C
MUCI R GGT ACC TCC TCT CAC CTC CTC CAA
ST3 F GGC GTG CCC GAC CCA TCT
ST3 R CGG CCC TCG TGC ACC TCA GTA A
K20 F AGA CCA AGG CCC GTT ACA G
K20 R ACG ACC TTG CCA TCC ACT ACT TC
K19 primers were designed to span exons 4 and 5, hence
spanning the shortest intron of the gene sequence, as well as incor-
porating mismatches between the pseudogene and cDNA
sequences in the 3¢ pentamers (Bader et al, 1988; Gunn et al,
1996). K16 primers were designed to span exons 1 and 3 at the
5¢ end thus avoiding the known sequence of K16 pseudogene, with
nested primers designed to span exons 1 and 2. b-actin PCR was
performed on each specimen as an endogenous external control for
RNA extraction and cDNA synthesis.
Polymerase chain reaction
PCR was carried out in a Hybaid Touchdown PCR machine
(Hybaid, Middlesex, UK) with an initial denaturation at 94°C and
final extension at 72°C common to all PCR reactions. Individual
assays were as follows:
K8: 35 cycles of 94°C 30 s, 61°C 30 s, 72°C 30 s
K16 outer: 40 cycles of 94°C 30 s, 59°C 30 s, 72°C 30 s
K16 nested: 35 cycles of 94°C 30 s, 59°C 30 s, 72°C 30 s
K19: 35 cycles of 94°C 30 s, 62°C 30 s, 72°C 30 s
Maspin: 35 cycles of 94°C 30 s, 50°C 30 s, 72°C 30 s
MUC1: 40 cycles of 94°C 30 s, 59°C 30 s, 72°C 30 s
ST 3: 35 cycles of 94°C 30 s, 56°C 30 s, 72°C 30 s
K20: 35 cycles of 94°C 30 s, 62.5°C 30 s, 72°C 30 s
The PCR mix consisted of 150 mM of each dNTP, 1 mM of each
primer, 1 ´ PCR buffer (Qiagen) and 0.5 units of Taq DNA poly-
merase (Qiagen) in a total volume of 10 ml. All PCR assays
included a DNA-positive control and a no-template negative
control. Five microlitre aliquots of the resulting PCR products
were examined on 0.5 mg ml–1 ethidium bromide stained, 2%
agarose/TAE gels for presence or absence of PCR products.
Analysis
Sensitivity of the assays was calculated on the group of patients
with histologically proven breast cancer by comparison of patients
with histologically evident lymph node metastases and patients
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patients with benign colorectal conditions confirmed on histology.
As all assays were expected to be more sensitive than histology,
specificity could only truly be determined by comparison against a
population with no histological evidence of cancer. For both sensi-
tivity and specificity 95% confidence intervals (95% CI) were
used to control for sample size (Merrie et al, 1998) as calculated
using CIA software (Gardner and Altman, 1989).
RESULTS
RT-PCR assays for K8, K16, K19, maspin and ST 3 were found
to be 100% sensitive compared to histology (Table 1), but with
considerable variation in the proportion of positive lymph nodes
from patients with breast cancer (Table 2). However, these markers
were not specific (Table 3), with transcripts of these genes detected
in many of the control lymph node samples tested
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Table 1 Patients with histologically confirmed breast cancer
Marker Number of Histologically Marker Sensitivity of
patients positive (%) positive (%) marker % (95% CI)
K 8 36 13 (36%) 35 (97%) 100 (75.3–100)
K 16 53 22 (42%) 38 (72%) 100 (84.6–100)
K 19 36 13 (36%) 35 (97%) 100 (75.3–100)
Maspin 9 9 (100%) 9 (100%) 100 (66.4–100)
MUC 1 18 10 (56%) 11 (61%) 60 (26.2–87.8)
ST 3 39 15 (38%) 37 (95%) 100 (78.2–100)
Table 2 Lymph nodes from patients with breast cancer
Marker Number of Histologically Marker positive
lymph nodes positive nodes (%) nodes (%)
K 8 313 56 (18%) 255 (81%)
K 16 476 90 (19%) 108 (23%)
K 19 313 56 (18%) 221 (71%)
Maspin 90 66 (73%) 50 (55%)
MUC 1 159 41 (26%) 28 (18%)
ST 3 342 69 (20%) 239 (70%)
Table 3 Non-cancer control patients
Marker Number of Marker Specificity of
patients positive marker % (95% CI)
K 8 8 8 0 (0–36.9)
K 16 22 10 54.5 (32.2–75.6)
K 19 11 9 18.2 (2.3–51.8)
K 20 35 0 100 (90.0–100)
Maspin 13 11 15.4 (1.9–45.5)
MUC 1 10 4 60 (26.2–87.8)
ST 3 9 9 0 (0–33.6)
Table 4 Lymph nodes from non-cancer patients
Marker Number of Marker positive
lymph nodes nodes (%)
K 8 54 52 (96%)
K 16 146 26 (18%)
K 19 61 41 (67%)
K 20 249 0 (0%)
Maspin 113 54 (48%)
MUC 1 90 44 (49%)



















Figure 1 Ethidium bromide stained agarose gels of RT-PCR products of potential markers for detection of submicroscopic spread of breast cancer. Lanes
1–10 represent ten lymph nodes from a patient without cancer (A) K8, (B) K16, (C) K19, (D) Maspin, (E) ST3. (F) K20, demonstrating lack of epithelial cell
contamination in the control lymph nodes with PCR product present only in the normal colonic epithelia (Lane N)(Table 4, Figure 1). Expression of MUC1 was found to be both
poorly sensitive and non-specific. K20 expression was not evident
in any of the control lymph nodes assessed (Tables 3 and 4).
Initial assessment of K16 using a limited number of controls
showed only two out of 52 lymph nodes from eight patients to be
K16 RT-PCR-positive, however, extension of the control assess-
ment to 146 nodes from 22 patients showed that 26 lymph nodes in
ten patients without epithelial malignancy were K16 RT-PCR-
positive (Table 3).
DISCUSSION
There have been several studies attempting to define markers for
the detection of submicroscopic disease in breast cancer, with
apparently convincing results for CEA, K19 and maspin (Table 5).
However, data from studies assessing the detection of disease in
colon and lung cancer have raised questions with regard to the
tissue specificity of these markers (Adams et al, 1995; Burchill et
al, 1995; Hoon et al, 1995; Krismann et al, 1995; Denis et al, 1997;
Dingemans et al, 1997; Eltahir et al, 1998)
CEA gene expression must be regarded with caution as a
tumour specific marker, as it has been detected by nested RT-PCR
in normal tissues. Jonas et al (1996) found 23% of controls without
cancer had evidence of CEA expression in peripheral blood, which
the authors propose may be due to venepuncture-induced skin
contamination. More recently, Liefers et al (1998) used the nested
CEA RT-PCR assay developed by Gerhard et al (1994) for the
detection of disease in lymph nodes. However, only seven lymph
nodes from two patients were used as controls and CEA expres-
sion was detected in these at high cycle numbers. These results
raise doubt with regards to the 100% tissue specificity reported by
Gerhard et al (1994) (Table 5).
The results from this study confirm a lack of tissue specificity
for both MUC-1 and K19 gene expression. Two previous reports
have suggested MUC-1 to be tissue specific (Noguchi et al, 1994,
1996a); however, there is no reported data on the number of
control patients, and a total of only ten lymph nodes assessed. Our
results concur with that of other groups in showing that MUC-1 is
expressed in cells of lymphohaemopoetic origin (Hoon et al, 1995;
Eltahir et al, 1998). Several studies in breast cancer have reported
K19 to be a tissue-specific marker (Datta et al, 1994; Schoenfeld
et al, 1994, 1996, 1997; Noguchi et al, 1996a; Eltahir et al, 1998;
Lockett et al, 1998). However, there is now a substantial body
of evidence to show that K19 can also be detected in peripheral
blood and lymphatic tissue rendering it unsuitable as a specific
marker of submicroscopic disease (Adams et al, 1995; Burchill et
al, 1995; Krismann et al, 1995; Denis et al, 1997; Dingemans et al,
1997).
In contrast to Luppi et al (1996) we did not find that maspin
proved to be a specific marker of occult tumour spread in breast
cancer. Using the primers and conditions reported by Luppi et al,
the maspin gene product could not be amplified in the T47-D and
MCF-7 cell lines or in genomic DNA. Analysis of these primers
revealed a 5 bp (base pair) self-dimer at the 3´ end of the forward
primer, a double 3 bp self-dimer in the reverse primer and a 4 bp
pair dimer between the two primers, resulting in marked primer
dimer formation and poorly specific priming of the maspin gene.
Custom PCR primers (Gibco BRL) were subsequently redesigned
using PrimerSelect (DNASTAR) with considerably less primer
dimer formation and straightforward amplification of the maspin
gene product. Using the redesigned primers maspin gene expres-
sion was found to vary markedly between tumours, and was
evident in many control nodes. In addition to this the MCF-7 cell
line did not display evidence of maspin expression (Figure 2).
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Table 5 Control patients and results from reported breast markers
Reference Marker Tissue Number Marker Specificity of
of patients positive marker % (95% CI)
Matsumura and Tarin, 1992 CD44 PBL 4 0 100 (39.8–100)
Eltahir et al, 1998 CD44 PBL 10 4 60 (26.2–87.8)
Gerhard et al, 1994 CEA BM/PBL 56 0 100 (93.6–100)
Mori et al, 1995 CEA LN 5 0 100 (47.8–100)
Brown et al, 1995 DF 3 PBL 4 0 100 (39.8–100)
Brown et al, 1995 K 18 PBL 4 4 0 (0–60.2)
Schoenfeld et al, 1994 K 19 LN 11 0 100 (71.5–100)
Datta et al, 1994 K 19 PBL 10 0 94.9 (82.7–99.4)
BM 29 2
Schoenfeld, 1996 K 19 LN 20 0 100 (83.2–100)
Luppi et al, 1996 K 19 PBL 17 5 70.6 (44–89.7)
Noguchi et al, 1996a K 19 LN (10)* (0)* –
Schoenfeld et al, 1997 K 19 PBL/BM 25 0 100 (86.3–100)
Eltahir et al, 1998 K 19 PBL 5 0 100 (47.8–100)
Lockett et al, 1998 K 19 LN 9 0 100 (66.4–100)
c-myc
PIP
Luppi et al, 1996 Maspin PBL 17 0 100 (83.9–100)
BM 4
Noguchi et al, 1994 MUC 1 LN (10)* (0)* –
Hoon et al, 1995 MUC 1 PBL 8 7 12.5 (3.1–52.7)
LN (8)* (4)*
Eltahir et al, 1998 MUC 1 PBL 23 21 8.7 (1.1–28.0)
Specificity of previously reported markers for the detection of submicroscopic spread of breast cancer. BM, bone marrow; LN, lymph nodes; PBL, peripheral
blood leucocytes. *number of lymph nodes only, patient numbers not reported.Although K16 expression appeared less ubiquitous compared to
other genetic markers, it also lacked specificity, as did ST3 and
K8. With regards to K16, assessment of only ten lymph nodes as in
previous studies (Noguchi et al, 1994, 1996a), would have resulted
in a false assertion of 100% specificity. However, when the
number of control nodes was increased to 154 from 23 patients, a
more accurate determination of specificity was possible.
Although many previous studies have reported 100% speci-
ficity, analysis of 95% confidence intervals (Table 5) shows that
the majority cannot make this claim with any degree of certainty.
Use of a large control group increases the reliability of the deter-
mination of specificity, and examination of too few patients can
result in false estimates.
We have adopted rigorous protocols to avoid and monitor for
epithelial cell contamination. This is achieved by strategically
separating component parts of the RT-PCR assay, the use of sterile
DNA-free techniques, disposable consumables, reagent only nega-
tive controls, reverse transcriptase minus controls and PCR
reagent only controls. The adherence to such methodology is
essential for success of any RT-PCR assay. The absence of K20 in
the control lymph nodes rules out the possibility of epithelial cell
contamination from the gastrointestinal tract, confirming the
validity of the positive results of the potential markers.
To date there have been no markers of submicroscopic spread of
breast cancer identified that are both sensitive and specific. Many
markers such as K19 and maspin have been initially reported as
sensitive and specific, but little emphasis has been placed on deter-
mining assay specificity to a reliable level.
Markers of submicroscopic spread in breast cancer could have
potential therapeutic impact, especially when combined with
sentinel node assessment of axillary disease. As yet no such
marker exists and future assays must be assessed by the use of
control populations of sufficient size to reliably determine speci-
ficity as well as sensitivity.
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